Eylea patents are due to run out from 2023 to 2032; however, these should not be taken as definite dates as there are many ways drug companies can extend their patents, for example, by changing the formulation of their product. In fact, Regeneron recently extended the original patent term of May 23, 2020, to June 16, 2023.

The current patent expiry dates for Eylea are as follows:

• Composition of matter (for a composition of at least 2 ingredients): June 16, 2023
• Formulation patents (4 of these): June 14, 2027 (for 2); June 21, 2027; March 22, 2026
• Methods of treatment patents (3 of these): March 22, 2026, and January 11, 2032 (for 2)
• Method of manufacturing: March 22, 2026
• Composition of matter (supplementary protection certificate): May 23, 2025.

Because pharmaceutical companies make about 80% of their overall revenue while their drug is on patent, they will often try many legal techniques to extend their patents for as long as they can. Once patents fully expire, generic companies can copy the formulation, saving the cost of years of research, and undercutting the original company’s prices significantly.